Preventative oral vancomycin reduces the incidence of C. difficle during allogeneic hematopoietic stem cell transplantation, according to a study by Pittsburgh-based University of Pennsylvania ...

Fecal microbiota transplant was noninferior to vancomycin as the initial treatment for C. diff in a randomized, open-label trial. Transplant showed slightly higher cure rates without recurrence and ...

C. diff is a horrible disease that can cause significant morbidity. It can and often does recur and kills around 30,000 Americans every year. We have made progress in prevention and treatment, but ...

The antibiotic vancomycin, recommended as first-line treatment for infection caused by the deadly superbug C. difficile (C. diff), may not be living up to its promise, according to new research. The ...

ATLANTA -- A tapered and pulsed course of vancomycin was not significantly better than a standard course of the drug for treating a first or second recurrence of Clostridioides difficile infection, a ...

In a phase-one human clinical trial, a pharmacist researcher has demonstrated that a new antibiotic, called Omadacycline, may be a promising tool in combating the superbug known as C diff which causes ...

I am 78 years old and in fair health.

There are inherent risks in biotech investing. A decade’s worth and often hundreds of millions of dollars in R&D, along with binary risks of failed clinical trials or regulatory approval. Above and ...

The bacterium Clostridioides difficile is one of the most common infections picked up in hospitals, and, even once it’s cleared from the body, patients have a 1 in 6 chance of catching it again within ...

Anne J. Gonzales-Luna, research assistant professor in the Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, is reporting the weakening of ...